Facephi H1 2026 slides: first positive cash flow amid revenue reset

Facephi forecast 2026 revenue of €32.5 million, down 9.7% from 2025 and 29% below its initial €46 million expectation, as a shift to post-consumption billing delays revenue recognition. Offsetting this, the company reported first-time positive LTM free cash flow of €1.1 million, with gross banking debt down to €6.6 million and leverage at 0.7x EBITDA. ARR rose 6% to €29.8 million and TCV increased 16% to €76.1 million; Facephi also launched its Intelligence Platform, though revenue remains concentrated in Latin America and banking.

Analysis

The key underwriting question is whether Facephi has improved the economics of its contracts or merely shifted when revenue and cash appear. Post-consumption billing can make reported growth look weak during transition, but it also removes the benefit of upfront customer financing and increases exposure to usage, implementation, and collection timing. Positive FCF is encouraging, yet €1.1m against €9.4m of LTM normalized EBITDA implies only modest cash conversion; the €0.9m FY26 FCF outlook offers little cushion if collections slip or refinancing is delayed.

ARR and TCV growth are not yet proof of durable monetization. The €20m of pending invoicing should be treated as a conversion test—not equivalent to recognized revenue or collected cash—until management shows timing, usage, and collection rates. Continued concentration in LATAM banking leaves results exposed to regional budgets and a narrow buyer set. The platform launch could improve cross-sell economics, but the onboarding-heavy mix and limited EMEA contribution make execution, not product breadth, the near-term determinant.

Over 1–3 months, watch FY26 revenue/EBITDA delivery, cash collection, and completion of the syndicated-loan refinancing. Over 6–18 months, evidence of EMEA wins and multi-product adoption could support a rerating; absent that, the auditor change and weak cash conversion may sustain a governance/quality discount. Contrarian angle: the revenue downgrade may overstate deterioration in demand, but the market is right to discount contract metrics until they convert into cash.

Key Decisions for Investors

• No near-term directional trade is compelling on the supplied evidence. Avoid adding solely on the low share price or headline TCV/ARR growth; verify trading liquidity and the actual terms of the refinancing before sizing any position.
• For existing exposure, make the thesis conditional on cash realization: track collections against the cited pending invoicing, FY26 FCF versus the €0.9m outlook, and whether leverage remains below 1.0x. A miss on cash generation or refinancing completion would weaken the case more than a timing-driven revenue shortfall alone.
• Treat the platform strategy as a 6–18 month catalyst, not a current earnings driver. Look for disclosed cross-sell/renewal evidence and material EMEA revenue progress; continued negligible diversification would falsify the expansion thesis.
• Do not use TCV as a substitute for backlog or cash-flow diligence. Request contract-level disclosure on consumption, invoicing schedules, cancellations, and collection rates; absent that, keep valuation assumptions conservative.